{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-089263","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.329525+00:00","generated_at":"2026-05-31T13:47:52.137415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ultragenyx Q2 revenue $147M (+36% YoY), raises 2024 guidance; key FDA agreements advance pipeline","bullets":["Q2 total revenue $147M (Crysvita $114M, Dojolvi $19M); net loss narrows to $132M from $160M.","2024 revenue guidance raised to $530-550M (prev $500-530M); Crysvita expected towards upper end of $375-400M.","Cash $874M after June equity offering of $381M net; 2024 operating cash use guided below $400M.","FDA agrees CSF heparan sulfate as surrogate endpoint for UX111 Sanfilippo accelerated approval; BLA filing late-2024/early-2025.","Positive Phase 3 data for DTX401 in GSDIa (41.3% reduction in cornstarch, p<0.0001); Phase 2/3 OI setrusumab shows 67% fracture reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-089263","json":"https://secwatch.observer/filing/0000950170-24-089263.json","markdown":"https://secwatch.observer/filing/0000950170-24-089263.md","text":"https://secwatch.observer/filing/0000950170-24-089263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024089263/0000950170-24-089263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024089263/rare-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:47:52.137415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}